The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Individualizing the selection of JAK inhibitors for patients with myelofibrosis
In this video, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the individualization of JAK inhibitor selection for patients with myelofibrosis (MF), highlighting the importance of considering platelet counts, anemia, and comorbidities when choosing between pacritinib, ruxolitinib, momelotinib, and fedratinib. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
